Barclays PLC Boosts Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target to $49.00

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had its price objective hoisted by research analysts at Barclays PLC from $46.00 to $49.00 in a research report issued to clients and investors on Thursday, October 26th. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Barclays PLC’s target price points to a potential downside of 9.53% from the company’s previous close.

A number of other brokerages also recently weighed in on SRPT. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $76.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 16th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. Morgan Stanley upgraded shares of Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and set a $60.00 price target for the company in a research report on Monday, October 2nd. BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Robert W. Baird restated an “outperform” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $63.59.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $54.16 on Thursday. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same quarter in the prior year, the business earned ($0.95) EPS. sell-side analysts expect that Sarepta Therapeutics will post -3.11 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Barclays PLC Boosts Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target to $49.00” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/11/13/sarepta-therapeutics-inc-srpt-price-target-increased-to-49-00-by-analysts-at-barclays-plc.html.

In related news, SVP Shamim Ruff sold 10,000 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 9.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its holdings in shares of Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 129 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Advisor Group Inc. lifted its position in Sarepta Therapeutics by 3.2% in the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after buying an additional 326 shares during the last quarter. Legal & General Group Plc lifted its position in Sarepta Therapeutics by 3.9% in the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after buying an additional 663 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in shares of Sarepta Therapeutics by 0.8% during the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after purchasing an additional 818 shares during the last quarter. 67.76% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply